Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human immunodeficiency virus-associated dementia.

J C McArthur1, N Sacktor, O Selnes

  • 1Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.

Seminars in Neurology
|March 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 years.

Brain, behavior, & immunity - health·2022
Same author

Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection.

Molecular neurobiology·2018
Same author

7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests.

AJNR. American journal of neuroradiology·2018
Same author

International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271.

Journal of neurovirology·2016
Same author

Brain morphometric correlates of metabolic variables in HIV: the CHARTER study.

Journal of neurovirology·2014
Same author

Characterizing HIV medication adherence for virologic success among individuals living with HIV/AIDS: Experience with the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) cohort.

Journal of HIV/AIDS & social services·2014

HIV-associated dementia affects 15-20% of advanced HIV patients, causing cognitive decline. Antiretroviral therapy can improve outcomes and reverse some neurological deficits.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Immunology

Background:

  • HIV-associated dementia (HAD) is a leading cause of dementia in young adults.
  • Affects 15-20% of individuals with advanced HIV disease, with 10,000 new US cases annually.
  • Characterized by psychomotor slowing, memory impairment, brain atrophy, and neuronal loss.

Purpose of the Study:

  • To outline the clinical and pathological features of HIV-associated dementia.
  • To discuss the impact of antiretroviral therapy on HAD incidence and outcomes.

Main Methods:

  • Review of clinical and pathological data related to HIV-associated dementia.
  • Analysis of the role of macrophage and microglia infection and activation in HAD pathogenesis.
  • Evaluation of the effects of antiretroviral therapy on neurological deficits.

Related Experiment Videos

Main Results:

  • Pathology involves macrophage/microglia infection, activation, and cytokine release.
  • Antiretroviral therapy has reduced HAD incidence rates.
  • Partial reversal of neurological deficits is achievable with treatment.

Conclusions:

  • HIV-associated dementia presents with progressive cognitive and motor decline.
  • Understanding the neuropathology is crucial for developing effective treatments.
  • Antiretroviral therapy offers a positive impact on managing HAD.